The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism

Mutations in ADNP were recently identified as a frequent cause of syndromic autism, characterized by deficits in social communication and interaction and restricted, repetitive behavioral patterns. Based on its functional domains, ADNP is a presumed transcription factor. The gene interacts closely with the SWI/SNF complex by direct and experimentally verified binding of its C‐terminus to three of its core components. A detailed and systematic clinical assessment of the symptoms observed in our patients allows a detailed comparison with the symptoms observed in other SWI/SNF disorders. While the mutational mechanism of the first 10 patients identified suggested a gain of function mechanism, an 11th patient reported here is predicted haploinsufficient. The latter observation may raise hope for therapy, as addition of NAP, a neuroprotective octapeptide named after the first three amino acids of the sequence NAPVSPIQ, has been reported by others to ameliorate some of the cognitive abnormalities observed in a knockout mouse model. It is concluded that detailed clinical and molecular studies on larger cohorts of patients are necessary to establish a better insight in the genotype phenotype correlation and in the mutational mechanism. © 2014 Wiley Periodicals, Inc.

[1]  R. Kooy,et al.  Challenges and opportunities in the investigation of unexplained intellectual disability using family‐based whole‐exome sequencing , 2015, Clinical genetics.

[2]  I. Gozes,et al.  Davunetide: Peptide therapeutic in neurological disorders. , 2014, Current medicinal chemistry.

[3]  C. Hultman,et al.  The familial risk of autism. , 2014, JAMA.

[4]  Z. Warren,et al.  Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014 , 2018, Morbidity and mortality weekly report. Surveillance summaries.

[5]  Stephen J. Guter,et al.  Convergence of Genes and Cellular Pathways Dysregulated in Autism Spectrum Disorders , 2014, American journal of human genetics.

[6]  Kali T. Witherspoon,et al.  A SWI/SNF related autism syndrome caused by de novo mutations in ADNP , 2014, Nature Genetics.

[7]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[8]  J. Shendure,et al.  A de novo convergence of autism genetics and molecular neuroscience , 2014, Trends in Neurosciences.

[9]  A. V. Vulto-van Silfhout,et al.  Coffin–Siris Syndrome and the BAF Complex: Genotype–Phenotype Study in 63 Patients , 2013, Human mutation.

[10]  Magalie S Leduc,et al.  Clinical whole-exome sequencing for the diagnosis of mendelian disorders. , 2013, The New England journal of medicine.

[11]  Y. Fukushima,et al.  Clinical correlations of mutations affecting six components of the SWI/SNF complex: Detailed description of 21 patients and a review of the literature , 2013, American journal of medical genetics. Part A.

[12]  S. Scherer,et al.  Autism spectrum disorder in the genetics clinic: a review , 2013, Clinical genetics.

[13]  Wei Wu,et al.  From neural development to cognition: unexpected roles for chromatin , 2013, Nature Reviews Genetics.

[14]  Eric M. Morrow,et al.  Using Whole-Exome Sequencing to Identify Inherited Causes of Autism , 2013, Neuron.

[15]  I. Gozes,et al.  NAP Alpha-Aminoisobutyric Acid (IsoNAP) , 2013, Journal of Molecular Neuroscience.

[16]  Bradley P. Coe,et al.  Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders , 2012, Science.

[17]  I. Gozes,et al.  The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective Activities , 2012, PloS one.

[18]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[19]  D. Horn,et al.  Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study , 2012, The Lancet.

[20]  Allan Jacobson,et al.  NMD: a multifaceted response to premature translational termination , 2012, Nature Reviews Molecular Cell Biology.

[21]  J. Veltman,et al.  De novo mutations in human genetic disease , 2012, Nature Reviews Genetics.

[22]  Tadashi Kaname,et al.  New from NPG , 2012, Nature Medicine.

[23]  Bradley P. Coe,et al.  Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations , 2012, Nature.

[24]  R. Kooy,et al.  Advances in understanding fragile X syndrome and related disorders , 2011, Current opinion in pediatrics.

[25]  Kathryn Roeder,et al.  Multiple Recurrent De Novo CNVs, Including Duplications of the 7q11.23 Williams Syndrome Region, Are Strongly Associated with Autism , 2011, Neuron.

[26]  I. Gozes,et al.  Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia , 2011, European Neuropsychopharmacology.

[27]  I. Gozes Microtubules, schizophrenia and cognitive behavior: Preclinical development of davunetide (NAP) as a peptide-drug candidate , 2011, Peptides.

[28]  W. Fischle,et al.  HP1 Recruits Activity-Dependent Neuroprotective Protein to H3K9me3 Marked Pericentromeric Heterochromatin for Silencing of Major Satellite Repeats , 2011, PloS one.

[29]  Christian Gilissen,et al.  A de novo paradigm for mental retardation , 2010, Nature Genetics.

[30]  Gary D Bader,et al.  Functional impact of global rare copy number variation in autism spectrum disorders , 2010, Nature.

[31]  G. Crabtree,et al.  Chromatin remodelling during development , 2010, Nature.

[32]  G. B. Schaefer,et al.  Genetic evaluation of autism. , 2008, Seminars in pediatric neurology.

[33]  J. Quinn,et al.  Expression of activity-dependent neuroprotective protein in the brain of adult rats. , 2008, Histology and histopathology.

[34]  I. Gozes,et al.  ADNP Differential Nucleus/Cytoplasm Localization in Neurons Suggests Multiple Roles in Neuronal Differentiation and Maintenance , 2008, Journal of Molecular Neuroscience.

[35]  I. Gozes,et al.  Activity-dependent Neuroprotective Protein Constitutes a Novel Element in the SWI/SNF Chromatin Remodeling Complex* , 2007, Journal of Biological Chemistry.

[36]  O. Touloumi,et al.  Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model , 2007, Journal of Pharmacology and Experimental Therapeutics.

[37]  R. Aebersold,et al.  An Essential Switch in Subunit Composition of a Chromatin Remodeling Complex during Neural Development , 2007, Neuron.

[38]  G. Rechavi,et al.  Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. , 2007, Developmental biology.

[39]  Christian von Mering,et al.  STRING 7—recent developments in the integration and prediction of protein interactions , 2006, Nucleic Acids Res..

[40]  I. Gozes,et al.  NAP mechanisms of neuroprotection , 2007, Journal of Molecular Neuroscience.

[41]  Bruce H. Morimoto,et al.  NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). , 2006, CNS drug reviews.

[42]  I. Gozes,et al.  Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. , 2004, Neuron glia biology.

[43]  A. Goldsweig,et al.  Activity-dependent neuroprotective protein: a novel gene essential for brain formation. , 2003, Brain research. Developmental brain research.

[44]  Douglas Wahlsten,et al.  In search of a better mouse test , 2003, Trends in Neurosciences.

[45]  I. Gozes,et al.  NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death , 2002, Stroke.

[46]  E. Seroussi,et al.  Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein* , 2001, The Journal of Biological Chemistry.

[47]  I. Gozes,et al.  A Novel VIP Responsive Gene: Activity Dependent Neuroprotective Protein , 2000, Annals of the New York Academy of Sciences.

[48]  I. Gozes,et al.  Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. , 2000, The Journal of pharmacology and experimental therapeutics.

[49]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[50]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[51]  H. Bassan,et al.  Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide , 1999, Journal of neurochemistry.

[52]  S. Said Molecules that protect: the defense of neurons and other cells. , 1996, The Journal of clinical investigation.

[53]  C. Gillberg,et al.  A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. , 1989, Journal of child psychology and psychiatry, and allied disciplines.

[54]  J. Garland The New England Journal of Medicine. , 1961, Canadian Medical Association journal.

[55]  S. Folstein,et al.  Genetic influences and infantile autism , 1977, Nature.